NCT05642182View on ClinicalTrials.gov

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

July 31, 2025

Conditions
Psoriasis
Interventions
DRUG

SFA002

Study drug formula without excipient

DRUG

SFA002

Study Drug SFA002 with excipient (Propionate)

Trial Locations (3)

19140

RECRUITING

Temple University, Philadelphia

33060

RECRUITING

NuLine Clinical Trial Center, Pompano Beach

58104

RECRUITING

Axis Clincals USA/ Red River Research Patners. LLC, Fargo

Sponsors

Lead Sponsor

SFA Therapeutics
All Listed Sponsors
lead

SFA Therapeutics

INDUSTRY

NCT05642182 - Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques | Biotech Hunter | Biotech Hunter